Boc-3-Hydroxy-1-Adamantyl-D-Glycine CAS 361442-00-4 Purity >99.5% E.E >99.5%
Ruifu Chemical Supply Related Intermediates
CAS 361442-04-8
CAS 945667-22-1
(R)-(-)-3-Aminopiperidine Dihydrochloride CAS 334618-23-4
Boc-3-Hydroxy-1-Adamantyl-D-Glycine CAS 361442-00-4
CAS 361440-67-7
(R)-1-Boc-3-Aminopiperidine CAS 188111-79-7
Chemical Name | Boc-3-Hydroxy-1-Adamantyl-D-Glycine |
Synonyms | (2S)-2-((tert-Butoxycarbonyl)amino)-2-(3-Hydroxyadamantan-1-yl)acetic Acid |
CAS Number | 361442-00-4 |
CAT Number | RF-PI1989 |
Stock Status | In Stock, Production Scale Up to Tons |
Molecular Formula | C17H27NO5 |
Molecular Weight | 325.40 |
Boiling Point | 497.3±20.0℃ |
Density | 1.296 |
Brand | Ruifu Chemical |
Item | Specifications |
Appearance | White or Off-White Crystalline Powder |
Water (K.F) | <0.50% |
Loss on Drying | <1.00% |
Residue on Ignition | <0.50% |
Single Impurity | <0.50% |
Total Impurities | <0.50% |
E.E | >99.5% |
Purity | >99.5% |
Infrared Spectrum | Conforms to Structure |
Test Standard | Enterprise Standard |
Usage | Pharmaceutical Intermediates |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture
Boc-3-Hydroxy-1-Adamantyl-D-Glycine (CAS: 361442-00-4) is an intermediate of API (CAS: 361442-04-8). API (CAS: 361442-04-8) is a potent and selective reversible inhibitor of dipeptidyl peptidase-4, which is being developed for the treatment of type 2 diabetes. It is absorbed rapidly after oral administration and has a pharmacokinetic profile compatible with once daily dosing. It is a dipeptidyl peptidase-4 (DPP-4) inhibitor antidiabetic for the treatment of type 2 diabetes. DPP-4 inhibitors are a class of compounds that work by affecting the action of natural hormones in the body called incretins. It is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. It is not for treating type 1 diabetes. It is sometimes used in combination with other diabetes medications. It was reached by the cooperation of AstraZeneca and Bristol-Myers Squibb Company and belongs to DPP-IV inhibitor.